Abstracts Archive - Page 1789 of 2607 - ACR Meeting Abstracts

Abstract Number: 2854 • 2016 ACR/ARHP Annual Meeting
Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
Andressa Mathias¹, Alessandra Dellavance², José Sá³, Felipe Muramoto⁴, Valdecir Marvulle⁵ and Luis Eduardo C. Andrade⁶, ¹Immunology Division, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Infomation Technology Department, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ⁴Information Technology Departmente, Fleury Medicine and Health Laboratories, SAO PAULO, Brazil, ⁵Statistics Department, Universidade Federal de São Paulo, SAO PAULO, Brazil, ⁶Rheumatology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: The nuclear dense fine speckled (DFS) pattern observed in the ANA assay on HEp-2 cells is strongly associated with autoantibodies to the 70/75kD lens…
Abstract Number: 2855 • 2016 ACR/ARHP Annual Meeting
The Long-Term Clinical Outcomes of Lupus Nephritis
Julie Davidson¹, Qinggong Fu², Beulah Ji³, Sapna Rao⁴, David Roth⁵, Laurence S Magder⁶ and Michelle Petri⁷, ¹Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ³Clinical Development, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ⁴Real World Evidence, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵GSK, Philadelphia, PA, ⁶Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical trials in lupus nephritis have often been designed to demonstrate renal response (or remission) following therapy based on categorical remission endpoints (often no…
Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Yuko Sakuma¹, Tatsuo Nagai², Taku Yoshio³ and Shunsei Hirohata⁴, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Jichi Medical University, Tochigi, Japan, ⁴Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 2858 • 2016 ACR/ARHP Annual Meeting
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Huihua Ding¹, Ling Qin¹, Samantha Stanley¹, Ramesh Saxena² and Chandra Mohan³, ¹Biomedical Engineering Department, University of Houston, Houston, TX, ²Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is the leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). The objective of this study is to validate…
Abstract Number: 2859 • 2016 ACR/ARHP Annual Meeting
Health-Related Interference of Social Activities and Suicidal Ideation in Systemic Lupus Erythematosus: Georgians Organized Against Lupus Cohort
Charmayne M. Dunlop-Thomas¹, Gaobin Bao², S. Sam Lim² and Cristina Drenkard³, ¹Medicine/Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Social integration has been found to be a protective factor from suicide-related ideation even after adjusting for mental health predictors. This is especially…
Abstract Number: 2860 • 2016 ACR/ARHP Annual Meeting
Exercise Significantly Improves Cardiorespiratory Fitness and Reduces Disease-Related Fatigue without Adverse Effects on Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-Analysis
Tom O'Dwyer¹, Laura Durcan² and Fiona Wilson³, ¹Physiotherapy, Trinity College Dublin, Dublin, Ireland, ²University of Washington, Seattle, WA, ³Physiotherapy, Trinity College, Dublin, Ireland
Background/Purpose: Systemic lupus erythematous (SLE) associates with accelerated mortality, frequently attributable to cardiovascular (CV) causes, which is not fully explained by traditional CV risk factors.…
Abstract Number: 2861 • 2016 ACR/ARHP Annual Meeting
Proportions of Circulating Follicular Helper T Cells and Complement Levels, White Blood Cell Counts, and Skin Manifestations in Patients with Active Systemic Lupus Erythematosus
Jun Kikuchi¹, Masaru Takeshita¹, Katsuya Suzuki², Yoshiaki Kassai³, Takahiro Miyazaki³ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan
Background/Purpose: Although circulating B cells and T cells, including follicular helper T (Tfh) cells, are reported to be involved in systemic lupus erythematosus (SLE) 1,2),…
Abstract Number: 2862 • 2016 ACR/ARHP Annual Meeting
Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity
Samantha Slight-Webb¹, Krista M. Bean¹, Joseph Kheir¹, Bolanle Adebayo¹, Holden T. Maecker², Paul J. Utz³, Judith A. James⁴ and Joel M. Guthridge⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by periods of heightened disease activity. Disease flares significantly affect quality of life and…
Abstract Number: 2863 • 2016 ACR/ARHP Annual Meeting
High Frequency of Terminally Differentiated CD8+ T Cells Characterize Systemic Lupus Erythematosus Patients with Renal Involvement
Nataly Manjarrez-Orduño¹, Laurence Menard¹, Julie Carman¹, Suzanne Suchard¹, Francesca Casano¹, Deborah Lee¹, Sium Habte¹, Sherif Daouti², Selena Kansal³, Dana Banas³, Can Jiang³, Dawn Stetsko³, Mark Cunningham³, Vivek Jayaswal⁴, Somnath Bandyopadhyay³, Sarah Hu³, Richard A. Furie⁵ and Steven G. Nadler⁶, ¹Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NY, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Biocon Bristol-Myers Squibb Research Center, Bangalore, India, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: SLE is a highly heterogeneous disease. The identification of disease subtypes with different pathological mechanisms is crucial to identify subjects with different disease progression…
Abstract Number: 2864 • 2016 ACR/ARHP Annual Meeting
Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study
Yanhua Sarah Hu¹, S Bandyopadhyay¹, Julie Carman², Nataly Manjarrez-Orduño², Can Jiang¹, Suzanne Suchard², Laurence Menard², sium habte¹, selena kansal¹, vivek jayaswal³, Richard A. Furie⁴ and Steven G. Nadler⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ³Biocon Bristol-Myers Squibb Research Center, Bangalore, NJ, India, ⁴Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ⁵Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, relapsing autoimmune disease affecting multiple organs and is a highly heterogeneous condition, with wide variations in the…
Abstract Number: 2865 • 2016 ACR/ARHP Annual Meeting
Apoptotic Microparticles, but Not Exosomes, Induce an Inflammatory Response in Synoviocytes
Brittany Bettendorf¹, Elizabeth Mitton-Fitzgerald², Claudia Gohr³ and Ann K. Rosenthal⁴, ¹Rheumatology, Medical College of Wisconsin, MIlwaukee, WI, ²Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁴Division of Rheumatology, Medical College of WI, Milwaukee, WI
Background/Purpose: Circulating microparticles (MPs) and exosomes modulate immune responses and play a role in the pathogenesis of systemic lupus erythematosus (SLE). Exosomes are 50-250 nm…
Abstract Number: 2866 • 2016 ACR/ARHP Annual Meeting
Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity
Carolyne K. Smith¹, Nickie Seto¹, Anuradha Vivekanandan-Giri², Wenmin Yuan³, Martin Playford⁴, Zerai G. Manna⁵, Sarfaraz A. Hasni⁶, Rui Kuai³, Nehal N. Mehta⁴, Anna Schwendeman³, Subramaniam Pennathur² and Mariana Kaplan⁷, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Internal Medicine/Nephrology, University of Michigan Nephrology, Ann Arbor, MI, ³Department of Medicinal Chemistry and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, ⁴NHLBI, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Lupus Clinical Research Program, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD
Background/Purpose: Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to down-regulation of TLR-induced inflammatory responses.…
Abstract Number: 2867 • 2016 ACR/ARHP Annual Meeting
Aberrant Epigenetic Alterations at the Promoter up-Regulate cAMP Responsive Element Modulator Alpha in CD4+ T Cells from Patients with Systemic Lupus Erythematosus
Qing Zhang¹, Huilin Zhang², Shu Ding³, Hai Long⁴, Yi Zhan², Xiangning Qiu⁴ and Qianjin Lu⁴, ¹Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China, ²Second Xiangya Hospital, Central South University, Changsha, China, ³Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, China, ⁴Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Recently, accumulating studies have documented that up-regulated cAMP responsive element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in T cells plays…
Abstract Number: 2868 • 2016 ACR/ARHP Annual Meeting
NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature
Kelly Hudspeth¹, Shu Wang², Jingya Wang², Saifur Rahman², Michael Smith², Kerry Casey², Geoffrey Stephens³, Miguel Sanjuan², Autoimmunity Molecular Medicine group², Zerai G. Manna⁴, Sarfaraz Hasni⁴, Rachel Ettinger⁵ and Richard Siegel⁶, ¹Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Respiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, ³Respiratory, Inflammatory, and Autoimmune Diseases Research, Medimmune, LLC, Gaithersburg, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ⁶Immunoregulation Section, Autoimmunity Branch and Office of the Clinical Director National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder whose pathology appears to involve many immune cell types. While it is clear that autoantibody…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].